While NLRP3 variants associated with CAPS are typically considered gain-of-function due to their dominant phenotype, most in vitro studies rely on the bacterial trigger lipopolysaccharide (LPS) to induce the activation of these inflammasomes. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.